Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16164523 | 1.00 | HSP90AA1 (0.34) | HSP90AA1P2RX7HKDC1PPARGKCNH2 | |
| SCHEMBL15464685 | 0.85 | HSP90AA1 (0.33) | HSP90AA1P2RX7HKDC1PPARG | |
| SCHEMBL5020297 | 0.85 | HSP90AA1 (0.33) | HSP90AA1P2RX7HKDC1PPARG | |
| SCHEMBL5020366 | 0.83 | CCR1 (0.41) | HSP90AA1P2RX7HKDC1PPARGKCNH2 | |
| SCHEMBL882865 | 0.82 | HSP90AA1 (0.38) | HSP90AA1P2RX7HKDC1PPARGKCNH2 | |
| SCHEMBL10273698 | 0.82 | HSP90AA1 (0.38) | HSP90AA1P2RX7HKDC1PPARGKCNH2 | |
| SCHEMBL882894 | 0.82 | HSP90AA1 (0.38) | HSP90AA1P2RX7HKDC1PPARGKCNH2 | |
| SCHEMBL876825 | 0.82 | P2RX7 (0.36) | HSP90AA1P2RX7HKDC1PPARG | |
| SCHEMBL882995 | 0.81 | P2RX7 (0.40) | HSP90AA1P2RX7HKDC1PPARGKCNH2 | |
| SCHEMBL5020378 | 0.81 | GRM5 (0.37) | HSP90AA1P2RX7HKDC1PPARGKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | HSP90AA1 2350/4885P2RX7 630/4885HKDC1 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.